Roche’s much-awaited treatment for haemophilia A, Hemlibra (emicizumab/ACE910), has been approved by the FDA for patients with Factor VIII inhibitors. Roche also announced the data for the non-inhibitor community, wherein Hemlibra successfully met both the primary as well as the secondary endpoint. The second front to provide fillip to the share price was the positive top-line data from another eagerly-followed trial IMpower 150, evaluating checkpoint inhibitor Tecentriq’s combina
21 Nov 2017
Multiple wins make the day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Multiple wins make the day
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
21 Nov 2017 -
Author:
Kamla Singh -
Pages:
3
Roche’s much-awaited treatment for haemophilia A, Hemlibra (emicizumab/ACE910), has been approved by the FDA for patients with Factor VIII inhibitors. Roche also announced the data for the non-inhibitor community, wherein Hemlibra successfully met both the primary as well as the secondary endpoint. The second front to provide fillip to the share price was the positive top-line data from another eagerly-followed trial IMpower 150, evaluating checkpoint inhibitor Tecentriq’s combina